52 patents
Utility
Amorphous solid dispersions
16 Jan 24
The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
Peng Li
Filed: 16 Mar 22
Utility
Organic compounds
19 Dec 23
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
Filed: 9 Sep 20
Utility
Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A
12 Dec 23
The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.
David Kass, Toru Hashimoto, Lawrence Wennogle, Joseph Hendrick, Robert Davis
Filed: 31 Jan 19
Utility
Amorphous solid dispersions
28 Nov 23
The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
Peng Li
Filed: 13 Apr 22
Utility
Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate
7 Nov 23
The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
Peng Li, Robert Davis
Filed: 24 Jan 22
Utility
Transmucosal methods for treating psychiatric and neurological conditions
7 Nov 23
The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.
Peng Li, Wei Yao, Robert Davis
Filed: 3 Jun 21
Utility
Organic compounds
3 Oct 23
The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
Filed: 19 Jul 22
Utility
Uses
19 Sep 23
The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.
David Kass, Toru Hashimoto, Lawrence P. Wennogle, Joseph Hendrick, Robert Davis
Filed: 3 Jun 20
Utility
4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
12 Sep 23
Peng Li, Robert E Davis, Kimberly Vanover
Filed: 10 Dec 20
Utility
Organic compounds
15 Aug 23
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
Wei Yao, Peng Li
Filed: 19 Jul 21
Utility
Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
4 Jul 23
The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
Peng Li, Robert Davis
Filed: 27 May 21
Utility
Organic compounds
24 Jan 23
This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
Sharon Mates, Peng Li, Lawrence P. Wennogle, Robert Davis
Filed: 16 Dec 20
Utility
Uses
22 Nov 22
The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries.
Lawrence P. Wennogle
Filed: 20 May 20
Utility
Organic compounds
8 Nov 22
The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists.
Peng Li, Youyi Peng, Lawrence P. Wennogle, Qiang Zhang
Filed: 22 May 18
Utility
PDE1 inhibitors for ophthalmic disorders
11 Oct 22
Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure.
Robert Davis, Allen Fienberg
Filed: 24 Feb 10
Utility
Substituted heterocycle fused gamma-carbolines synthesis
27 Sep 22
The present invention provides improved methods for the preparation of substituted heterocycle fused gamma-carbolines, intermediates useful in producing them and methods for producing such intermediates and such heterocycle fused gamma-carbolines.
Peng Li, Qiang Zhang
Filed: 16 Aug 19
Utility
Salts and crystals
13 Sep 22
The disclosure provides new, stable, pharmaceutically acceptable hydrochloride salt forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
Lawrence P. Wennogle, Peng Li, Edwin Aret
Filed: 26 Sep 18
Utility
Organic compounds
30 Aug 22
The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
Filed: 20 Jul 18
Utility
Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline
9 Aug 22
John Charles Tomesch, Peng Li, Qiang Zhang, Andrew S. Thompson
Filed: 7 Oct 19
Utility
Organic compounds
5 Jul 22
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the μ-opioid receptor.
Peng Li, Wei Yao, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
Filed: 20 Jul 18